GoFibre provides full fibre and wireless broadband infrastructure, primarily targeting underserved rural communities across the UK.
Since incorporation, the company has secured five fundraisings totalling £177m, including a £164m investment in January 2022 backed by British Strategic Investment Fund I and II.
It is worth noting that three of these five fundraisings include debt raises, and in December 2023, the business was acquired by asset management firm Gresham House.
Part of the rapid online grocery delivery revolution, Zapp is a mobile app that promises to deliver groceries, snacks, and other essential products in 20 minutes or less.
Zapp’s key differentiator is that, unlike other grocery delivery companies like Getir and Gorillas, Zapp is available 24/7. Zapp is expanding rapidly and now operates in London, Manchester, Cambridge, Bristol, Paris, Rotterdam, and Amsterdam.
Zapp was launched in November 2020 by Joe Falter, along with his co-founder Navid Hadzaad, a former product leader at Amazon’s Seattle HQ. Since then, the company has secured £186m in funding, with investors including Lightspeed, Atomico, 468 Capital and Burda.
Juvenescence is a biotech company focused on developing therapeutics that aim to extend healthy human lifespan.
Operating across biotechnology, clinical research, and AI-enabled drug discovery, the company has raised £186m across four fundraisings. Recent backers include M42 and Foresite Capital, with a £57.4m round completed in April 2025.
In June 2025, Juvenescence acquired US-based AI company Ro5, expanding its portfolio.
Quell Therapeutics develops regulatory T cell (Treg) therapies for treating autoimmune diseases and preventing transplant rejection.
A spinout from King’s College London and University College London, the company has secured a total of £213m in equity funding across five rounds, with backers including Syncona, AstraZeneca, Jeito Capital, and Point72.
In addition to receiving an R&D grant from AstraZeneca in 2023, Quell reported turnover of £9.16m in its latest financials, and has a post-money valuation of £285m.
ElevenLabs develops AI-powered tools for translating spoken content across languages, with applications in media, gaming, and enterprise software.
The company has raised £224m across four funding rounds, with participation from Andreessen Horowitz, Sequoia Capital, Salesforce Ventures, and Deutsche Telekom. In 2024, ElevenLabs joined the Disney Accelerator and later acquired the voice technology firm Omnivore.
Its latest fundraising was in January 2025, when ElevenLabs raised £145m.
Exohood Labs provides multidisciplinary R&D services across artificial intelligence, blockchain, renewable energy, and quantum computing. The company has raised £232m in equity funding since incorporation, through two rounds backed by Livsquare Capital, which now holds a 20% stake.
Its activities span clinical diagnostics, energy systems, robotics, and space infrastructure, serving clients across the private, public, and third sectors.
Spur Therapeutics develops and commercialises gene therapies for treating or preventing bleeding disorders.
A spinout from University College London, the company has raised £233m across seven equity rounds, with early backing from Syncona Partners, AlbionVC, and late-stage support from Novo Holdings and Wellington Management. The company has also received five Innovate UK grants totalling £2.45m.
In August 2020, Spur Therapeutics listed on NASDAQ under the ticker FRLN, raising $159m at IPO.
MeiraGTx develops gene therapies for both inherited and acquired disorders, with a focus on technologies that enable the manipulation of cellular signalling.
Another spinout from University College London, the company has raised £233m across eight equity rounds, with investors including AlbionVC, Perceptive Advisors, Sanofi, and Essex Bio-Technology. The company also underwent an IPO on NASDAQ in 2018, generating $75m at listing.
MeiraGTx has also made one acquisition — US-based gene therapy firm Vector Neurosciences.
COMPASS Pathways develops psilocybin-based drugs for the treatment of mental health disorders, including depression.
The company has raised £237m across seven equity fundraisings, with participation from investors such as RA Capital, Founders Fund, ATAI Life Sciences, and Vivo Capital.
It listed on NASDAQ in September 2020 under the ticker CMPS, raising $147m at IPO.
As of its latest fundraising, COMPASS Pathways’ latest post-money valuation is £259m.
Apollo Therapeutics develops medical therapies targeting cancer, inflammatory conditions, and rare diseases.
The company, which was spun out of the University of Cambridge and University College London in 2016, and subsequently incorporated in 2021. Since then, Apollo Therapeutics has raised £248m across three equity fundraisings, with investors including M&G Investments, Patient Square Capital, and Johnson & Johnson Innovation.
The company reported £4.86m in turnover for 2024 and spent over £16m on R&D during the same period.
CellCentric is a University of Cambridge spinout developing cancer therapeutics targeting epigenetic regulation.
Another pharmaceutical company making our top 15 tech startups, CellCentric has raised £248m across 19 equity rounds, with recent backers including Avego Bioscience Capital, RA Capital, and BrightEdge.
It has also received four Innovate UK grants totalling £2.45m and has been awarded six patents across 15 authorities globally. The company was acquired by 5Y Capital in 2016.
Verdiva Bio develops cardiometabolic drugs targeting obesity and related conditions. The company raised £335m in a single equity round in October 2024, backed by RA Capital, OrbiMed, General Atlantic, Forbion Capital Partners, and Lilly Asia Ventures.
Incorporated in 2024, the founding team includes former senior figures from Gyroscope Therapeutics and MiroBio, both of which were acquired by a large pharmaceutical firm.
Nothing (also trading as Nothing Technology) develops smart consumer electronic products, such as mobile phones and earphones.
The company has raised £338m to date, including a £30m loan fundraising from the Small Business Bank. Nothing’s most recent equity round raised £75.9m to fund international expansion into the US and grow its existing product and technology portfolio.
A new entry to this list, Isomorphic Labs is developing a drug discovery platform that uses AI models to design new pharmaceuticals.
Spun out from Google in 2021, the company has raised £464m so far through a single funding round in 2025, backed by Alphabet, GV (Google Ventures), and Thrive Capital. In the same year, it recorded £49.1m in R&D expenditure and employed 71 staff.
Due to its high-profile spinout status and large investment activity, Isomorphic Labs has been featured on several Beauhurst high-growth features, including the top UK companies backed by corporate funds, London’s top startups, and The Artificial Intelligence Top 100 UK.
Topping our list of UK tech startups is Bicycle Therapeutics, a pharmaceuticals startup that develops medicines based on bicyclic peptides for the treatment of diseases, including cancer.
A spinout from the University of Cambridge, the company has raised £673m across seven equity fundraisings, alongside six Innovate UK grants totalling £5.25m. In 2019, it listed on NASDAQ under the ticker BCYC, raising $60.7m at IPO.
The company reported £28.2m in turnover in 2024 and spent £113.8m on R&D, with backing from investors such as Atlas Venture, Novartis Bioventures, and SR One. It holds granted patents and remains a majority institutionally owned entity.
